ライフサイエンスコーパス: body surface

1 ctivity that may shape the microbiome on the body surface.

2 ulcerated lesions covering up to 70% of the body surface.

3 the distributed sensor network placed on the body surface.

4 pheral thermosensory neurons innervating the body surface.

5 ght that is scattered and reflected from the body surface.

6 uity for pain across multiple regions of the body surface.

7 tion of OBAP1 with other proteins in the oil body surface.

8 void or slow down the mucus loss through its body surface.

9 those neurons and be transported back to the body surface.

10 play key roles in immunity and tolerance at body surfaces.

11 tion of long-lived adaptive immune memory at body surfaces.

12 for use on the face or on other curvilinear body surfaces.

13 significantly higher (P < 0.05) on external body surfaces.

14 ls may be revealed by reflections from their body surface [4-7].

15 minescent sources due to reflection from the body surface [5, 6].

16 irectly detecting current shear across their body surface [5] or indirectly assessing drift direction

17 fect the quality of different hair types and body surface according to exposure routine.

18 ection of microorganisms inhabiting the host body surface and cavities, shapes a micro-environment fo

19 Body surface and epicardial potentials were recorded sim

20 with five receptor types, covers the entire body surface and expands deep into the pharynx.

21 ral regions that help them to move about the body surface and feed on skin and gill debris.

22 For all body surface and intracardiac leads, both Delta(alternan

23 isture; (b) uptaking water; (c) cleaning the body surface; and (d) fastening the body on a smooth sur

24 Body surfaces are colonized by resident microbes that ar

25 Patients with LVH (LVM/body surface area >/=116 and >/=96 g/m(2) in men and wom

26 ea <=1 cm(2) or aortic valve area indexed to body surface area <=0.6 cm(2)/m(2) and mean aortic press

27 ence in age (65+/-10 versus 59+/-13; P=0.5), body surface area (2.0+/-0.2 versus 2.0+/-0.2 m(2); P=0.

28 29%]) or based on body weight (10 [48%]) and body surface area (4 [19%]).

29 atients with aortic valve area normalized to body surface area (AVA/BSA) <0.6 cm(2)/m(2); yet, this c

30 pigmentation of 0.5% or more of their facial body surface area (BSA) and 3% or more of their non-faci

31 effective diameters at each level to patient body surface area (BSA) and sex.

32 scores for common measurements adjusted for body surface area (BSA) and stratified by age, sex, race

33 ss index (BMI; weight (kg)/height (m)2), and body surface area (BSA) at ages 7-13 years and birth wei

34 Recorded variables included maximal body surface area (BSA) detachment, SCORTEN (Score of To

35 Body surface area (BSA) of vitiligo lesions.RESULTS Pati

36 Body surface area (BSA) scaling has been used for prescr

37 End-systolic volume and end-diastolic volume/body surface area (BSA) were 62 (45-101) and 104 (83-143

38 nalysis, log-creatinine, sex, age, race, and body surface area (BSA) were significantly associated wi

39 ncer was higher for participants with a high body surface area (BSA), great height, or excess weight

40 Body surface area (BSA)-adjusted chronic kidney disease

41 Cardiac output was indexed to body surface area (cardiac index [CI]) for all analyses.

42 zation, and echocardiography) and indexed to body surface area (cardiac index [CI]).

43 LVM indexed to body surface area (LVMI) and MWT were significantly high

44 After adjusting for age (P = .090), body surface area (P = .073), and sex (P = .005), pulmon

45 f prior Puestow procedure (P = 0.018), lower body surface area (P = 0.048), higher islet equivalents

46 ated using pectoralis muscle area indexed to body surface area (pectoralis muscle index).

47 ed with increasing body mass (r = -0.41) and body surface area (r = -0.37).

48 y with age (r=0.848), body length (r=0.871), body surface area (r=0.856), and body weight (r=0.825) a

49 LVEF of >/=50% but stroke volume indexed to body surface area (SVi) of </=35 ml m(-2); and 629 (54%)

50 lly injured, as demonstrated by mean % total body surface area (TBSA) (41.2 +/- 18.3 for adults and 5

51 included in the analysis, with a mean total body surface area (TBSA) burn of 7.2% and a mean age of

52 ll transfusion strategy in 20% or more total body surface area (TBSA) burn patients.

53 ned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomi

54 jects is 42.5 +/- 16.0 years, the mean total body surface area (TBSA) burned is 18.5 +/- 16.4%, and t

55 rn survivors aged >=18 years with >=5% total body surface area (TBSA) or burns to critical areas.

56 llitus (1.45 [1.39-1.51]), obesity in women (body surface area 2.2 versus 1.8: 1.44 [1.35-1.53]), fem

57 than those with hypertension (LA volume max/ body surface area 30.2+/-6.6 versus 33.0+/-9.0 mL/m(2);

58 of sunscreen per 1 cm2 was applied to 75% of body surface area 4 times per day for 4 days, and 30 blo

59 4 [16.9] mL/min/1.73m(2), LV mass indexed to body surface area 60.7 [11.9] g/m(2)), 90 had evaluable

60 -diastolic volume (LVDV) was 40 mL (LVDV per body surface area [BSA], 25 mL/m(2)); left ventricular e

61 aluated whether the effect of clinical (age, body surface area [BSA], chronic kidney disease [CKD], a

62 easurements were corrected for age, sex, and body surface area according to reference data and progno

63 ered intravenously) or cisplatin (70 mg/m(2) body surface area administered intravenously) on day 1 o

64 erity Index [EASI] score >=16, percentage of body surface area affected >=10%, and Peak Pruritus Nume

65 reased in a stepwise fashion with increasing body surface area affected by PsO (P for trend <0.001).

66 8-32 years]) were all male with an estimated body surface area affected with RDEB of 4% to 30%.

67 evere psoriasis defined by 3% or more of the body surface area affected.

68 significant reduction in LV mass indexed to body surface area after 6 months, which may account in p

69 3 x 10(6) CAR-NKT cells per square meter of body surface area after lymphodepleting conditioning wit

70 ace area before vs. 58.9 +/- 17.5 mL/min per body surface area after therapy; P = 0.22); however, 3 p

71 lied with verteporfin at a dose of 6 mg/m(2) body surface area and a 689 nm diode laser for 83 second

72 unilateral pectoralis muscle mass indexed to body surface area and attenuation (approximated by mean

73 cases, such as severe burns on >30% of total body surface area and EB.

74 ion of the myocardium, indexed ECV (iECV) to body surface area and late gadolinium enhancement.

75 6 weeks in LV end-systolic volume indexed to body surface area and LV global longitudinal strain both

76 es in end-diastolic volume indexed (EDVi) to body surface area and the ejection fraction (EF).

77 ns, necessary program experience, donor with body surface area appropriate for recipient, and improve

78 en product was applied at 2 mg/cm2 to 75% of body surface area at 0 hours on day 1 and 4 times on day

79 , days in intensive care unit, sex, age, and body surface area at evaluation.

80 e or after therapy (64.2 +/- 16.5 mL/min per body surface area before vs. 58.9 +/- 17.5 mL/min per bo

81 0 [95% CI, 2.2-22.8]; p < 0.001), a detached body surface area between 10% and 29% (odds ratio, 3.7 [

82 ax laboratories and subjected to a 30% total body surface area burn injury.

83 andard deviation 17) years with median total body surface area burn of 15% [interquartile range (IQR)

84 12 male pediatric burn patients (>30% total body surface area burn) and 12 young, healthy male subje

85 ed the varying effects of patient age, total body surface area burn, and inhalation injury on the pro

86 owed that a burn size of more than 60% total body surface area burned (an increase from 40% a decade

87 urn care setting, adults with over 40% total body surface area burned and children with over 60% tota

88 area burned and children with over 60% total body surface area burned are at high risk for morbidity

89 of 612 burned children [52% +/- 1% of total body surface area burned, ages 0.5-14 years (boys); ages

90 ome after controlling for age, gender, total body surface area burned, and inhalation injury (hazard

91 Age, total body surface area burned, and inhalation injury were als

92 +/- 15 years old and with 38% +/- 14% total body surface area burned, underwent an oral glucose tole

93 tcomes was lower, at approximately 40% total body surface area burned.

94 le organ failure was approximately 60% total body surface area burned.

95 nts (>/=16 years old) with 20% or more total body surface area burns recruited from 6 US burn centers

96 hours after injury, and more than 20% total body surface area burns requiring at least one surgical

97 escribe a 22-year-old soldier with 19% total body surface area burns, polytrauma, and sequence- and c

98 rogen deprivation plus docetaxel (75 mg/m(2) body surface area every 3 weeks for 6 cycles) and RP.

99 ose of 0.75 (adjusted to 0.5 to 1.0) g/m2 of body surface area every 4 weeks for 6 months.

100 was the 6-month change in LV mass indexed to body surface area from baseline as measured by cardiac m

101 efore receiving an approximately 12.5% total body surface area full thickness burn.

102 based on CAC-CT radiomics, sex, height, and body surface area in a random training subset of 1587 pa

103 o monitor accurately and easily the affected body surface area in a standardized way.

104 ty as objectively determined by the affected body surface area in both unadjusted and adjusted analys

105 rdial infarction (1.24 [1.08-1.42]), and low body surface area in men (1.22 [1.14-1.30]).

106 twice daily) or dacarbazine (1000 mg/m(2) of body surface area intravenously every 3 weeks).

107 -day cycle and nab-paclitaxel 100 mg/m(2) of body surface area intravenously on days 1, 8, and 15 unt

108 moderate-to-severe chronic plaque psoriasis (body surface area involvement >/=10%, Physician's Global

109 ic records of patients with either SJS (<30% body surface area involvement) or TEN (> = 30% involveme

110 and 1242 women) aged 23.1+/-5.7 years, with body surface area of 1.9+/-0.2 m(2) and 8.9+/-4.9 years

111 57.1 and 53.6 years, respectively, P<0.0001; body surface area of 2.4 and 2.1 m(2), respectively, P<0

112 Fifty-four patients with burns to total body surface area of greater than or equal to 15%, intub

113 s of subcutaneous bortezomib (1.3 mg/m(2) of body surface area on days 1, 4, 8, 11, 22, 25, 29, and 3

114 des and the LV mass index (LVMI) (indexed to body surface area on echocardiography, 67 patients).

115 h cisplatin-based chemoradiation (40 mg/m(2) body surface area once per week with a planned total dos

116 ricular indexed end-diastolic volume >125 mL/body surface area raised to the 1.3 power was associated

117 Donor-to-recipient body surface area ratio <0.90 had a RR of 1.40 (1.13-1.7

118 Mean LV mass indexed to body surface area regression over 6 months was 2.6 g/m(2

119 ce: Standard dosing of chemotherapy based on body surface area results in marked interpatient variati

120 Body surface area seems to be appropriate for indexation

121 nt confirmed and then subjected to 30% total body surface area steam burn injury.

122 The animals were exposed to 40% total body surface area third degree skin flame burn and 48 br

123 rn injury greater than or equal to 20% total body surface area to our burn center from 2011 to 2016.

124 meter-derived diameter, which was divided by body surface area to produce an indexed annulus size.

125 The total body surface area was 33% (22%-52%).

126 METHODS AND LA volume indexed to body surface area was measured by cardiovascular magneti

127 h age, height, and weight, normalization for body surface area was most efficient in removing the eff

128 terquartile range) age, body mass index, and body surface area were 68 (57-77) years, 28 (24-34) kg/m

129 ney morphological characteristics indexed to body surface area were associated inversely and independ

130 3 (mild or moderate), and 3% to 20% affected body surface area were equally randomized for 8 weeks of

131 Dimensions corrected by body surface area were higher in men than in women at th

132 mTFC parameters indexed for body surface area were significantly more abnormal in pa

133 3DE LA volumes indexed by body surface area were similar in men and women and incr

134 Age, left ventricular mass, and body surface area were the main predictors of aortic dim

135 2015 and October 2018 with burns >=15% total body surface area with regard to infection and sepsis (S

136 males (27.8 +/- 2.7 years; 1.92 +/- 0.1 m(2) body surface area) and 10 females (25.4 +/- 3.9 years; 1

137 sed LV end-diastolic volume [EDV] indexed to body surface area) at baseline were excluded.

138 s in absolute and adjusted GS (corrected for body surface area) between 1 and 12 months after transpl

139 and efficacy of 32 doses of BTZ (1.3 mg/m of body surface area) in 10 highly sensitized kidney transp

140 ) and intravenous paclitaxel (175 mg/m(2) by body surface area) on day 1 of every 21-day cycle (contr

141 dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1, 8, and 15 of every 21-day

142 dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1, 8, and 15 of every 21-day

143 r >/=upper 90th percentile for age, sex, and body surface area) or not enlarged; the hazard of an adv

144 n [AUC 5 or 6] and paclitaxel 175 mg/m(2) of body surface area) or the same chemotherapy regimen plus

145 years) with severe burn injury (>= 20% total body surface area) to generate training and test dataset

146 sed cardiac index (cardiac output divided by body surface area) to incident all-cause dementia and Al

147 edian age 40 years, median burn size 6.0% of body surface area), 71% were men and 76% were White.

148 males (25.4 +/- 3.9 years; 1.68 +/- 0.1 m(2) body surface area), at rest and post maximal incremental

149 ce (n=121) of methotrexate (40-60 mg/m(2) of body surface area), docetaxel (30-40 mg/m(2)), or cetuxi

150 n 63 patients with major burns (>/=15% total body surface area).

151 rations as patients with larger burns (total body surface area, >/= 30%).

152 atients with moderate-to-severe AD (affected body surface area, >=10%; Eczema Area and Severity Index

153 Magna/Magna Ease valves were smaller (median body surface area, 1.42 versus 1.93 m(2); P=0.002) and y

154 olume (left ventricular end-diastolic volume/body surface area, 104+/-13 and 69+/-18 mL/m(2); P<0.001

155 .001; right ventricular end-diastolic volume/body surface area, 110+/-22 and 66+/-16 mL/m(2); P<0.001

156 7 burn patients (mean age, 26.9 years; total body surface area, 16.1%) received 415 laser sessions (2

157 with 2 infusions of rituximab, 500 mg/m2 of body surface area, 2 weeks apart, followed by 4 maintena

158 (SD) athlete height was 200.2 (8.8) cm; mean body surface area, 2.38 (0.19) m2.

159 Patients with lower burn severity (total body surface area, 20-30%) express similar metabolic alt

160 /-10 g/m(2); P<0.001; right ventricular mass/body surface area, 36+/-7 and 24+/-5 g/m(2); P<0.001) an

161 ight ventricular mass (left ventricular mass/body surface area, 96+/-13 and 62+/-10 g/m(2); P<0.001;

162 d 21-day cycles of gemcitabine (1000 mg/m(2) body surface area, administered intravenously on days 1

163 Total body surface area, age, and inhalation injury had signif

164 ndence after TP-IAT: (1) male sex, (2) lower body surface area, and (3) higher total IEQ per kilogram

165 on rate (eGFR) 25-75 mL/min per 1.73 m(2) of body surface area, and a urine albumin-to-creatinine rat

166 hysiology and Chronic Health Evaluation III, body surface area, and age, sarcopenia index was indepen

167 sociations of age, body length, body weight, body surface area, and heart rate on PAAT were investiga

168 sions, parameters of body size (body weight, body surface area, and organ circumference) and gestatio

169 mass and function after controlling for age, body surface area, and sex.

170 malizing to body weight, lean body mass, and body surface area, and simplified measurements were comp

171 tients, including 1476 with burns >20% total body surface area, by presence of AKI.

172 d-diastolic and -systolic volumes indexed to body surface area, ejection fraction, 24-hour ambulatory

173 l ventilation had a larger baseline detached body surface area, higher Logistic Organ Dysfunction sco

174 agnetic resonance measures for age, sex, and body surface area, particularly given the changing demog

175 Corrected for age, sex, and body surface area, right ventricular end-systolic volume

176 of stroke between 11 and 365 days were small body surface area, severe aortic calcification, and fall

177 After adjusting for age, race, body surface area, systolic blood pressure, history of h

178 45 mm, lowered toward 40 in females with low body surface area, TGFBR2 mutation, and severe extra-aor

179 Propensity matching based on age, sex, body surface area, total fluoroscopy time, and total acq

180 ed to the same suberythemal UVR dose, to 85% body surface area, using solar simulated UVR or narrowba

181 left atrial end-diastolic volume indexed to body surface area, were assessed using cine cardiovascul

182 e, 9-40 years) and were indexed according to body surface area, with internal validation (R(2) = 0.84

183 rsal scald burn injury covering 30% of total body surface area.

184 t of weight per moisturizer used for a given body surface area.

185 emales before but not after normalization to body surface area.

186 ere calculated for each variable adjusted to body surface area.

187 iligo involves an estimation of the affected body surface area.

188 y inverted after indexation of RV volumes to body surface area.

189 gnosed AD involving at least 5% of the total body surface area.

190 jected to a full-thickness burn of 30% total body surface area.

191 enting with marked systemic features and low body surface area.

192 dmitted with burns covering 52% of his total body surface area.

193 pression, particularly in those with smaller body surface area.

194 l vitiligo that involved 15% to 50% of total body surface area.

195 gen, panel reactive antibody >10%, and lower body surface area.

196 5) in end-systolic volume indexed (ESVi) to body surface area.

197 oving to 73% after accounting for individual body surface area.

198 on was positively correlated with weight and body surface area.

199 10-point scale), and AD on 10% or greater of body surface area.

200 ARVC patients, particularly when indexed to body surface area.

201 e also reduced with increasing body mass and body surface area.

202 g for clinical covariates, including age and body surface area.

203 associated with older current age and higher body surface area.

204 evaluated with cardiac MRI and normalized to body surface area.

205 e also identified between clinical measures (body surface area/BSA, pruritus ADQ, and transepidermal

206 -weekly cycles of paclitaxel [175 mg/m(2) of body surface area] and carboplatin [area under the curve

207 imum aortic-root-diameter z score indexed to body-surface area (hereafter, aortic-root z score) over

208 ne dose of 4.3 g or more per square meter of body-surface area (which has been associated with premat

209 rapy at a dose of 375 mg per square meter of body-surface area administered every 2 months for 3 year

210 of 30 to <90 ml per minute per 1.73 m(2) of body-surface area and albuminuria (ratio of albumin [mg]

211 f at least 40 ml per minute per 1.73 m(2) of body-surface area and had been receiving angiotensin-sys

212 ne (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched pl

213 axel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT a

214 usly at a dose of 175 mg per square meter of body-surface area every 3 weeks, plus carboplatin (dose

215 axel, at a dose of 75 mg per square meter of body-surface area every 3 weeks.

216 taxel at a dose of 75 mg per square meter of body-surface area every 3 weeks.

217 [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from baseline) and a decrease in the e

218 VESVI was 41.2+/-20.0 ml per square meter of body-surface area in the CABG-alone group and 43.2+/-20.

219 ients was 46.1+/-22.4 ml per square meter of body-surface area in the CABG-alone group and 49.6+/-31.

220 at least 3.0 ml per minute per 1.73 m(2) of body-surface area in the preceding year to receive allop

221 ients was 54.6+/-25.0 ml per square meter of body-surface area in the repair group and 60.7+/-31.5 ml

222 axel (at a dose of 25 mg per square meter of body-surface area intravenously every 3 weeks, plus pred

223 ore baseline (randomisation), 10% or greater body-surface area involvement at both screening and base

224 daily at a dose of 25 mg per square meter of body-surface area on a continuous dosing schedule (28-da

225 at a dose of 20 to 30 mg per square meter of body-surface area on a continuous dosing schedule (in 28

226 omib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11).

227 R of 25 to 65 ml per minute per 1.73 m(2) of body-surface area or 56 to 65 years of age with an estim

228 tered at a dose of 20 mg per square meter of body-surface area per day for 10 consecutive days in mon

229 alan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantat

230 f at least 30 ml per minute per 1.73 m(2) of body-surface area to receive either empagliflozin (at a

231 ease in the aortic-root diameter relative to body-surface area with either treatment.

232 VESVI was 52.6+/-27.7 ml per square meter of body-surface area with mitral-valve repair and 60.6+/-39

233 erapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantat

234 apy with intravenous fludarabine (30 mg/m(2) body-surface area) and cyclophosphamide (500 mg/m(2) bod

235 ceive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (cont

236 face area) and cyclophosphamide (500 mg/m(2) body-surface area) on days -5, -4, and -3.

237 ving cisplatin (>/=70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin.

238 ate [GFR] >60 ml per minute per 1.73 m(2) of body-surface area) to either a standard blood-pressure t

239 FR], 25 to 60 ml per minute per 1.73 m(2) of body-surface area) to receive an ACE inhibitor (lisinopr

240 ase (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear

241 ate, 25 to 60 ml per minute per 1.73 m(2) of body-surface area), and risks for cardiovascular disease

242 starting dose of everolimus depended on age, body-surface area, and concomitant use of cytochrome 3A4

243 less than 60 ml per minute per 1.73 m(2) of body-surface area, and diabetic retinopathy, or they had

244 40.0 to 99.9 ml per minute per 1.73 m(2) of body-surface area, and evidence of diabetic kidney disea

245 latin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 1

246 -1.51+/-1.33 ml per minute per 1.73 m(2) of body-surface area, respectively.

247 Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary

248 ion in the presence or absence of BI (15% of body surface burn) and determined the degree of immune c

249 Ants exploit differences in body surface chemistry to distinguish nestmates from col

250 1 uV change in the alternans voltage on the body surface, coronary sinus and left ventricle leads, r

251 al Clearance to Eradicate MRSA]) showed that body surface decolonisation reduced all-pathogen bloodst

252 ized in three parallel maps representing the body surface determine responses to second-order electro

253 On the body surface, different ectodermal organs exhibit distin

254 distribution of bacterial communities on the body surface during development of the model organism Hy

255 le basket catheters and simultaneous 57-lead body surface ECGs.

256 e of noninvasive imaging techniques based on body surface electrocardiographic mapping to elucidate t

257 iatrial geometry relative to an array of 252 body surface electrodes was obtained from a noncontrast

258 Human body-surface epithelia coexist in close association with

259 Many body surfaces harbor organ-specific gammadelta T cell co

260 hance not only the reflectivity of the ant's body surface in the visible and near-infrared range of t

261 In clinical data, body-surface-indexed EDV and ESV (mL/m(2)) were higher f

262 6 (38% [95% CI, 27 to 51%]) had GBS on their body surfaces, indicating vertical transmission.

263 g gene clusters can set up a two-dimensional body surface map.

264 rcardiography (QRS area), and multielectrode body surface mapping (standard deviation of activation t

265 Body surface mapping showed greater AF organization near

266 Body surface mapping showed that the area with ST-segmen

267 nts, endocardial, epicardial RV (CARTO), and body surface mapping was performed.

268 Patients wore a 252-electrode vest for body surface mapping.

269 in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet

270 al or tactile stimuli presented on their own body surface, or pictures of hands and feet within arm's

271 mation about spatio-temporal dynamics of the body surface potential (BSP) during atrial excitation.

272 able variance between simulated and measured body surface potential distributions.

273 Differences between the body surface potential extrema predicted with homogeneou

274 and ectopic activation, together with pseudo-body surface potential map ECGs in 2 of them.

275 Bipolar EGMs and body surface potential mapping do require HDF filtering

276 In body surface potential mapping maps, HDF filtering incre

277 ttern characterization in electrogram (EGM), body surface potential mapping, and electrocardiographic

278 METHODS AND EGM, body surface potential mapping, and electrocardiographic

279 situ pig hearts, estimating activation from body surface potential maps during sinus rhythm and loca

280 From 4 other anesthetized pigs, 64-lead body surface potential maps were recorded during sinus r

281 h endocardial and epicardial activation from body surface potential maps.

282 The relationship between epicardial and body surface potentials defines the forward problem of e

283 Body surface potentials were simulated from epicardial r

284 ) forward models were compared with measured body surface potentials.

285 picardial potentials are computed from known body surface potentials.

286 computation of epicardial electrograms from body surface potentials.

287 pic herpesviruses from the nervous system to body surfaces, referred to as anterograde axonal traffic

288 ildren with burns exceeding 30% of the total body surface, requiring at least 1 surgical procedure we

289 Although body surface scanning with a standard Geiger counter was

290 At the body surface, skin's stratified squamous epithelium is c

291 numbers of observed viral genotypes on many body surfaces studied, including the oral, gastrointesti

292 nismal functions are size-dependent whenever body surfaces supply body volumes.

293 on-invasive, non-contact modality to capture body surface temperature with the potential to reveal un

294 Additionally, we imaged the entire body surface to confirm known CS locations.

295 Airway epithelium is the first body surface to contact inhaled irritants and report dan

296 of tissue resident memory (TRM) cells at the body surfaces to provide a front line defence against in

297 regions of reentrant activity in AF from the body surface using electrocardiographic imaging, calibra

298 response against infections reencountered at body surfaces, where they accelerate pathogen clearance.

299 fin is added to the microrobot's cylindrical body surface, which biases the propulsion direction.

300 ed microglia coverage of the motoneuron cell body surface with time after injury and the presence of